GMED Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 12.68%. Globus Medical, Inc.'s return on equity of 10.08% beat Boston Scientific Corp.'s return on equity of 12.55%.

Globus Medical, Inc. has a consensus price target of $107.17, signalling upside risk potential of 18.88%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.78 which suggests that it could grow by 37.36%. Given that Boston Scientific Corp. has higher upside potential than Globus Medical, Inc., analysts believe Boston Scientific Corp. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.056, which suggesting that the stock is 5.621% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Globus Medical, Inc.'s net income of $119M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 29.13x while Boston Scientific Corp.'s PE ratio is 39.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.49x versus 5.68x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 27.89%. Globus Medical, Inc.'s return on equity of 10.08% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Globus Medical, Inc. has a consensus price target of $107.17, signalling upside risk potential of 18.88%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 22.18%. Given that Intuitive Surgical, Inc. has higher upside potential than Globus Medical, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.056, which suggesting that the stock is 5.621% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Globus Medical, Inc.'s net income of $119M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 29.13x while Intuitive Surgical, Inc.'s PE ratio is 63.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.49x versus 18.05x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 12.96%. Globus Medical, Inc.'s return on equity of 10.08% beat Insulet Corp.'s return on equity of 17.89%.

Globus Medical, Inc. has a consensus price target of $107.17, signalling upside risk potential of 18.88%. On the other hand Insulet Corp. has an analysts' consensus of $365.40 which suggests that it could grow by 42.77%. Given that Insulet Corp. has higher upside potential than Globus Medical, Inc., analysts believe Insulet Corp. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.056, which suggesting that the stock is 5.621% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.412, suggesting its more volatile than the S&P 500 by 41.175%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Insulet Corp. quarterly revenues of $783.8M. Globus Medical, Inc.'s net income of $119M is higher than Insulet Corp.'s net income of $101.6M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 29.13x while Insulet Corp.'s PE ratio is 73.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.49x versus 6.82x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 11.84%. Globus Medical, Inc.'s return on equity of 10.08% beat Stryker Corp.'s return on equity of 15.17%.

Globus Medical, Inc. has a consensus price target of $107.17, signalling upside risk potential of 18.88%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 12.48%. Given that Globus Medical, Inc. has higher upside potential than Stryker Corp., analysts believe Globus Medical, Inc. is more attractive than Stryker Corp..

Globus Medical, Inc. has a beta of 1.056, which suggesting that the stock is 5.621% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.88 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Globus Medical, Inc.'s net income of $119M is lower than Stryker Corp.'s net income of $849M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 29.13x while Stryker Corp.'s PE ratio is 44.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.49x versus 5.81x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.